Commonwealth Scientific and Industrial Research Organisation

Ludwig Institute for Cancer Research Limited

The University of Sydney

Thomas Charles Elleman

Thomas Peter John Garrett

Robert Nicholas Jorissen

Edouard Collins Nice

Timothy Edward Adams

Colin Wesley Ward

Neil Moreton McKern

George Oscar Lovrecz

Teresa Anne Domagala

Antony Wilkes Burgess

Antony Wilks Burgess

Herbert Rudolf Treutlein

Meizhen Lou

Vidanagamage Chandana Epa

Belinda J Anderson

John S Mattick

Colin Lesley Ward

Neil Morton McKern

The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules.

Truncated EGF receptor

The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF-&#x3b1;. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules.

The present invention relates to a method of designing compounds able to bind to a molecule of the EGF receptor family and to modulate the activity mediated by the receptor molecule based on the 3-D structure coordinates of the EGF receptor crystal of.

Method of designing agonists and antagonists to EGF receptor family

Antigenic preparations active against species of bacteria naturally producing Type 4 fimbriae, such as Bacteroides nodosus which causes footrot in sheep, are produced by culturing a suitable genetically engineered aerobic or facultatively anaerobic host bacterial cell such as Pseudomonas aeruginosa. The host cell contains the gene encoding the fimbrial structural subunit antigens of at least one strain of the said species of bacteria and an endogenous compatible system for the morphogenetic assembly of Type 4 fimbriae and/or the genes for the morphogenetic assembly of such fimbriae derived from a Type 4 fimbriate species. The genetically engineered host cells are cultured such that nature fimbriae are produced as extracellular structures and the fimbriae are harvested, substantially free of the host cells, for use as the antigenic preparation. In preferred embodiments of the invention the natural fimbrial subunit gene is modified to enhance expression in the new host. Antigenic preparations according to this invention have proven to be effective vaccines against footrot.

Method of producing an antigenic preparation

Growing community of inventors

Westmeadows, Australia

Thomas Charles Elleman